Disease relevance of AIDS-208002

• Xylotubercidin thus appears to have considerable potential for both topical and systemic treatment of HSV-2 infections [1].
• Xylotubercidin against herpes simplex virus type 2 in mice [1].
• Tubercidin, 5-chlorotubercidin, xylotubercidin, neplanocin A, thiosemicarbazone R, and 3-methylquercetine were too toxic to HeLa cells for their inhibitory effects on respiratory syncytial virus to be examined [2].

High impact information on AIDS-208002

• When applied topically at 0.25, 0.5, or 1% in dimethyl sulfoxide or when administered systemically (intraperitoneally) at 12.5 or 25 mg/kg per day, xylotubercidin suppressed the development of herpetic skin lesions and the paralysis and mortality associated therewith in hairless mice inoculated intracutaneously with HSV-2 [1].
• The in vitro activities of xylosyladenine and 3'-deoxyadenosine (in combination with 2'-deoxycoformycin) and xylotubercidin (as a single agent) were greater than or equivalent to that of araA (in combination with 2'-deoxycoformycin) [3].

Chemical compound and disease context of AIDS-208002

• Of a series of newly synthesized derivatives of the pyrrolo[2,3-d]pyrimidine nucleosides tubercidin, toyocamycin, and sangivamycin, the xylosyl analog of tubercidin, xylotubercidin, exhibited the greatest potency and selectivity against herpes simplex virus type 2 (HSV-2) in vitro [1].

Analytical, diagnostic and therapeutic context of AIDS-208002

• At dosage regimens that were not toxic for the host, xylotubercidin proved efficacious in various HSV-2 animal model infections [1].

References